Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related Macular Degeneration

To the Editor We recently reported a phase I dose-escalation study of the oral tyrosine kinase inhibitor vorolanib (previously known as X-82 [Tyrogenex]), which was used as a treatment for neovascular age-related macular degeneration (AMD). We have since been made aware of a 2008 report detailing 2 cases of neovascular AMD treated with oral sorafenib, which deserves mention. Like vorolanib, sorafenib is a multikinase inhibitor that has been used to treat cancer. It has theoretical utility as a treatment for wet AMD because it downregulates the production of vascular endothelial growth factor and platelet-derived growth factor.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research